HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DXM Distribution Legislation Clears House And Moves To Senate Again

This article was originally published in The Tan Sheet

Executive Summary

Legislation banning distribution of bulk dextromethorphan to people and businesses not registered with FDA passed the House with overwhelming support and moves to the Senate, where similar bills stalled in the two previous sessions

You may also be interested in...

Elections Reshape FDA Oversight Scene On Capitol Hill

The Republican takeover in the House shuffles the leadership in committees crucial to the dietary supplement and OTC drug industries while likely setting the stage for cuts to FDA funding.

FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action

Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run

FDA Panel To Weigh DXM Education, Sales Restrictions Against Scheduling

The continued availability of OTC dextromethorphan depends on convincing safety experts that less restrictive measures than scheduling DXM as a controlled substance will sufficiently reduce abuse

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts